Chronic myeloid leukemia (CML) in older patients has not been studied well. To assess the long-term outcome of older patients with Philadelphia-and/or BCR-ABL-positive CML, 199 patients aged X60 years representing 23% of 856 patients enrolled in the German randomized CML-studies I (interferon a (IFN) vs hydroxyurea (HU) vs busulfan (BU) and II (IFN+HU vs HU alone) were analyzed after a median observation time of 7 years. In all, 45 patients were treated with Bu, 63 with HU, and 91 with IFN. The 5-year survival was 38% in patients X60 years and 47% in patients o60 years (Po0.001). Whereas 5-year survival in chemotherapy-treated older patients was inferior to that in younger patients (33 vs 46%, P ¼ 0.006 for HU and 29 vs 38%, P ¼ 0.042 for Bu), no significant survival difference could be verified in IFN-treated patients (46 vs 53%, P ¼ 0.077). Calculation of age-adjusted, relative survival confirmed these results. Adverse effects of IFN were similar in both age groups, but IFN dosage to achieve treatment goals was lower in older patients. We conclude that the course of CML is not different in the elderly. They require lower IFN doses, achieve the same hematologic and cytogenetic response rates and the same survival advantage at comparable toxicity.
Introduction
The incidence of chronic myeloid leukemia (CML) increases with age. Annual age-specific incidence rate rises from less than 1 per 100 000 under the age of 40 years to 5 at the age of 65 years and exceeds 11 in the octogenarians with little variation worldwide. 1, 2 As a consequence, more than half of all patients diagnosed with CML are X60 years old. 2 Older patients are under-represented in the major interferon a (IFN) trials with only a quarter or less of the patients being X60 years. [3] [4] [5] [6] [7] The impact of age as a poor prognostic factor for survival has been well described. 8, 9 Older patients with CML in chronic phase have a lower performance status and live shorter than younger patients. 10, 11 Two studies reported in particular on IFN treatment and clinical characteristics of patients X60 years with CML in chronic phase. 12, 13 These patients had similar pretreatment characteristics as younger patients except for a more unfavorable risk profile also when the risk factor age was not considered. Uniformly, hematologic and cytogenetic response rates and overall survival were not significantly different between younger and older patients, but the median observation times in these studies were only 57 and 38 months, respectively. 13, 14 First-line therapeutic options for patients in chronic phase comprise IFN-based regimens, hydroxyurea (HU), allogeneic stem cell transplantation (SCT) with and without reduced intensity conditioning, and, more recently, imatinib. 15, 16 Allogeneic SCT as the only curative option is restricted, as a rule, to patients less than 55 years of age due to increased transplant-related mortality. Information on long-term survival and toxicity of imatinib will not be available for several years. In patients not eligible for allogeneic SCT, IFN-based therapies therefore remain standard in early chronic phase for the time being.
A major concern when older individuals are treated with IFNbased regimens has been the reported poorer tolerability. Older patients have been reported to only tolerate lower IFN doses, and dose adjustments are required more frequently (Shepherd et al. Blood 2001; 98: 727a; abstract) . In particular, neurotoxicity has been reported in 31% of patients X60 years 12, 17 and dose-limiting toxicity was observed in 26% of elderly patients as compared with 10-20% overall. 12 Here we report on the clinical features and long-term outcome of 199 patients X60 years with Philadelphia (Ph) and/or BCR-ABL-pos itive CML in chronic phase, enrolled and evaluable in the German randomized CML-studies I and II (recruitment 1983-1994) and observed for a median of 7 years.
Patients and methods

Patients and therapy
At diagnosis, 199 out of 856 Ph-and/or BCR-ABL-positive CML patients in chronic phase (23%) were 60 years of age or older. Patients stem from two consecutive, randomized studies (German CML-studies I (HU vs busulfan (Bu) vs IFN) and II (IFN+HU vs HU alone)) and were recruited from 7/1983 to 12/1994 . In both studies, inclusion criteria were newly diagnosed chronic phase CML, no prior therapy and treatment requirement as defined by the presence of at least one of the following criteria: unexplained fatigability, weight loss of more than 10% body weight in 6 months, fever exceeding 38.51C on five consecutive days, organomegaly-related symptoms, white blood cell (WBC) count of more than 50 Â 10 9 /l or platelet count of more than 1 Â 10 12 /l at the time of recruitment. They were randomized to receive either Bu, HU or IFN alone or in combination with HU. Of the 856 patients, 188 were treated with Bu, 308 with HU, and 360 with IFN-based therapy. Of the 199 patients who were 60 years or older (24% of 188), 45 were treated with Bu, 63 (21% of 308) with HU, and 91 (25% of 360) with IFN-based therapy.
There was no age limit. According to the study protocol, cytogenetic results were not required for randomization. Ph-and BCR/ABL-negative patients or patients with unknown Ph status were excluded later and analyzed separately. Chronic phase was defined as absence of any evidence of acceleration as described previously. 3 Blast crisis was diagnosed if blasts and promyelocytes were more than 30% of peripheral WBC or more than 50% of nucleated cells in the bone marrow or if extramedullary blastic infiltrations were present.
Detailed descriptions of the protocols of CML-studies I and II were published previously. (3, 18) In CML-study I, 516 out of 622 patients randomized to receive either HU (n ¼ 194), Bu (n ¼ 188), or IFN (n ¼ 134) were Ph/BCR-ABL positive and evaluable. In each treatment arm only monotherapy was allowed. Crossover of the drugs was permitted in case of treatment failure (no partial or complete hematologic remission within the first 4 months, loss of response in spite of doubling dosages of randomized therapy, intolerability). In CML-study II, 340 out of 376 patients randomized to receive the combination of IFN with HU (n ¼ 226) or HU alone (n ¼ 114) were Ph/BCR-ABL positive and evaluable. Bu (0.1 mg/kg/day) was given continuously (discontinuation at WBC count less than 20 Â 10 9 / L, resumption at 50 Â 10 9 /L). HU (40 mg/kg/day) was also given continuously with the goal of normal WBC counts. IFN-a2a (Roferon A s , Hoffmann-La Roche, Grenzach-Wyhlen, Germany) or IFN-a2b (Intron A s , Essex Pharma, Munich, Germany) was administered at a dose of 5 Â 10 6 IU/m 2 /day subcutaneously, adapted to WBC counts of 2-4 Â 10 9 /l and tolerability with only one preparation (Roferon A or Intron A) given by each participating center.
Response criteria
Complete hematologic remission was defined as normal WBC count with normal differential (WBC count less than 10 Â 10 9 /l, bands and metamyelocytes p5%), normal platelet count, no CML-related symptoms, and normal spleen size (not palpable or 12 cm maximum diameter). A partial hematologic remission was defined as a more than 50% decrease of WBC count or a WBC count p20 Â 10 9 /L). For cytogenetic analyses, 25 metaphases were analyzed whenever possible. Karyotypes with less than five metaphases were excluded from the analysis. If five to 10 metaphases were analyzed, the data were not used unless they fitted in a pattern obtained by previous or subsequent analyses or by concomitant quantitative reverse transcriptase polymerase chain reactions (RT-PCR) of BCR-ABL transcripts according to published procedures. 19, 20 Complete cytogenetic remission was defined as absence of any Ph-positive metaphase, partial and minor responses as decreases of Ph-positive cells to 1-34%, and 35-65%, respectively.
Adverse effects and follow-up
Adverse effects were reported according to the WHO toxicity criteria in four grades: mild, moderate, severe, life-threatening. Baseline 'adverse effects' recorded at the time of diagnosis were subtracted. Treatment was discontinued temporarily for grade 3 or 4 toxicity and permanently for unrelenting intolerable adverse effects.
Pretherapeutic diagnostic evaluation consisted of history, physical examination, complete blood cell count including reticulocytes, alkaline leukocyte phosphatase, serum lactate dehydrogenase (LDH), liver enzymes, cytogenetics, molecular analysis, and bone marrow cytology and histology.
Investigations at 6-monthly intervals included inquiry about symptoms (fever, fatigability, adverse drug effects), physical examination (spleen size, extramedullary manifestations, weight), complete blood cell count, LDH, liver enzymes, drug dosages, and cytogenetics in the IFN arm; investigations at 12-month intervals included cytogenetics and bone marrow cytology and histology. Additional investigations were documented at the end of chronic phase, beginning of blast crisis, and death.
Statistics
All analyses were performed following the intent-to-treat principle. Patients' data at baseline were compared using w 2 tests, Student's t-test, or Wilcoxon's two-sample test, as appropriate. Cox's proportional-hazard regression model was used for the analysis of prognostic factors. 21 Survival curves were estimated according to The corresponding test statistics was the log-rank test. 23 Relative survival was calculated by dividing each observed survival probability 24 by the expected survival probabilities of the general population matching sex, age, and calendar period of observation with the remaining patients at risk. The general population data were obtained from the Statistisches Bundesamt of Germany.
Ethics
The protocols followed the Declaration of Helsinki and were approved by the ethics committee of the Fakultät fü r Klinische Medizin Mannheim of the University Heidelberg and by the local ethics committees. Informed consent was obtained from all patients.
Results
Patients' characteristics
Baseline patients' characteristics are shown in Table 1 . The median age of patients X60 years was 66 years (range 60-85 years) with a significant female predominance (54.8 vs 37.1% in patients o60 years). The age distribution is shown in Figure 1 .
Patients X60 years presented with lower WBC counts (median 117 Â 10 9 vs 140 Â 10 9 /l), a higher rate of thrombocytosis, smaller spleen size, and lower rates of organomegalyrelated symptoms and fever at the time of diagnosis than patients o60 years. As expected, older patients had a worse Karnofsky index. The baseline characteristics with significant differences between the age groups had no influence on survival (Cox regression) except for age and spleen size, both covariates of the new CML score (www.pharmacoepi.de). While age represents a poor prognostic risk factor contributing to the less favourable risk profile in older patients, 9 the greater spleen size penalizes the younger patients (Table 1) .
Response rates
Hematologic and cytogenetic remission rates were similar in younger and older patients. In IFN-treated patients (Table 2) , overall hematologic remission (complete and partial) was observed in 74 of 91 patients X60 years (82%) and in 233 of 269 patients o60 years (87%). Cytogenetic remissions (partial and complete) were achieved in 58 (16.1%) of 360 IFN-treated patients (250 evaluable). In patients X60 years, remissions were observed in 13 patients (14%), four (4%) being partial and nine (10%) being complete as compared to 17% (n ¼ 45) in patients o60 years, 9% being partial (n ¼ 23) and 8% being complete (n ¼ 22). Hematologic remissions preceded cytogenetic remissions in all patients.
Adverse effects
The adverse effects observed in the IFN-treated patients are shown in Table 3 . Most frequent IFN-related adverse events were flu-like, gastrointestinal, and neuropsychiatric symptoms and local skin irritations. The frequencies of the adverse effects were not significantly different between the two age groups. The most adverse effects were WHO grades 1 and 2, and no death was attributable to IFN treatment.
Dose of interferon and discontinuation
The median daily dose of IFN administered was significantly lower (by about 12%) in older patients (2.571.6 vs 3.471.6 Â 10 6 IU/m 2 , P ¼ 0.011) (Figure 2a ). IFN doses declined steadily during the course of therapy, which was more pronounced in older patients. No differences were found for median WBC counts, the additionally administered HU dose (data not shown) and the median duration of IFN treatment, which was 17 and 18 months, respectively (Figure 2b) . The causes for IFN discontinuation were not very different between the two age groups except for BMT, which was performed only in the younger age group (Table 4) . 
Survival
Median follow-up was 7 years (10.8 years for patients from CML-study I and 6.2 years for patients from CML-study II). The 5-year survival was significantly shorter in older patients (38 vs 47%, Po0.001, Figure 3a ), but this difference was not evident in all the three treatment groups. Whereas the 5-year survival of patients who had received HU or Bu was significantly shorter in older patients (33 vs 46%, P ¼ 0.006, for HU-and 29 vs 38%, P ¼ 0.042, for Bu-treated patients (Figure 3c, d) ), the survival difference between IFN-treated patients did not reach significance (46 vs 53%; P ¼ 0.077, Figure 3b ). Likewise, median survival was shorter in older patients (48 vs 57 months overall, 9 1 2 1 5 1 8 2 1 2 4 3 0 3 6 4 8 6 0 7 2 8 4 9 6 1 0 Median interferon dosage (a), duration of interferon therapy (b) in patients o60 years vs X60 years during treatment of CML in chronic phase. Never received IFN (n=3) or IFN discontinued because of costs (n=1) c Colitis (n=2), myocardial infarction (n=1), cardiomyopathy (n=1), Raynaud's-syndrome (n=1), arthritis (n=1), bone marrow fibrosis (n=1), drug addiction (n=1), refusal (n=17), imatinib (n=1), vasculitis (n=1), sepsis (n=1), renal dysfunction (n=1), unknown (n=22). 
CML in the elderly
months with Bu). Due to the increasing influence of comorbidities in older patients, analysis of relative survival was carried out. 24 After adjustment for age, survival probabilities were almost identical in both groups of IFN-treated patients (5-year survival probabilities 52 vs 54%, Figure 4a ). In contrast, survival probabilities on HU or Bu treatment were clearly shorter in older patients also after age adjustment (Figure 4b, c) .
Survival analysis of older patients according to treatment disclosed a long-term survival advantage of IFN-treated patients, which was significant compared to Bu-treated patients (46 vs 29%, P ¼ 0.015) and borderline compared to HU-treated patients (46 vs 33%, P ¼ 0.064, Figure 5 ). Table 5 summarizes the causes of death. While the rates of leukemia-related causes of death (ie blast crisis, infection, hemorrhage) were similar for both age groups, older patients may have died more often from CML-unrelated causes.
Causes of death
Discussion
This analysis reports on age-specific clinical features and outcome of CML patients in chronic phase X60 years who were enrolled in two consecutive randomized trials comparing IFN, Bu, and HU. Perhaps, the most salient result of this analysis is that older patients incur no disadvantage, and likely benefit from IFN-based therapy. Elderly patients treated with IFN survive longer than those treated with HU or Bu. This information is clinically relevant in view of limited therapeutic options for elderly CML patients and a lack of long-term outcome data with Imatinib. 16 Data reporting treatment outcomes in the elderly are rare with no data available on patients at the age of 75 years or older since in most randomized trials older patients are under-represented due to age cutoff at 70 4, 6, 7, 25, 26 or 75 years. 5 The proportion of patients X60 years old of 23% within the German CML-studies I and II, which had no age limit, is therefore one of the highest available for detailed analysis.
Univariate analysis of baseline patients and laboratory characteristics did not reveal any significant difference by age that would suggest a more advanced stage of disease at presentation in older patients. Single institution trials 12, 13 (in total less than 55 patients studied) have reported several features that occurred with various levels of significance in elderly patients with chronic phase CML including female predominance, lower incidence of splenomegaly, 27 poorer performance status, hepatomegaly, 10 and higher median percentage of bone marrow blasts and basophils. 12 Of these, we can only confirm poorer performance status and female predominance. We found no evidence for age-specific biologic differences in the elderly with CML. In agreement with others, 12, 13 in our study hematologic and cytogenetic remission rates were similar in the two age groups.
In accordance with our previous study, IFN doses required to reach the therapeutic targets (low normal WBC at acceptable tolerability) declined with time, 4 but, overall, were 10-15% lower in the older age group. These lower doses, however, had no impact on hematologic and cytogenetic response rates and survival. This agrees with the recent report that lower IFN doses can achieve the same survival outcome as maximally tolerated doses (Shepherd et al. Blood 2001; 98: 727a; abstract) . It is noteworthy that elderly patients did not need more supplemental HU than younger patients to control WBC counts.
Adverse IFN effects were not very different between the two age groups contrary to the earlier notion that IFN is less well tolerated in the elderly. 12, 13 IFN was well tolerated in the majority of patients without major differences of IFN compliance between the age groups as shown in Table 3 . The requirement of lower IFN dosage in the elderly may have contributed to this finding. Previous reports to the contrary analyzed much smaller sample numbers and did not determine IFN dosage. 12, 13 Severe toxicities occurred only in a minority of patients, were reversible and did not adversely influence the rates of IFN discontinuation in the elderly. No fatalities due to IFN were observed. Pegylated IFN, a depot formulation of IFN with a more favorable adverse effects profile, may improve IFN tolerability and enhance efficacy in the future (Lipton et al. Blood 2002; 100: 782a; abstract) There is evidence from randomized trials that the combination of IFN with cytarabine or HU improves survival and/or response rates. 13, 26, 28 Whereas the combination of IFN and HU is well tolerated, the combination of IFN with cytarabine may be associated with increased toxicity.
In conclusion, our series of 199 patients is the largest reporting on the long-term outcome of patients 60 years or older with CML to date. We found no evidence that CML in the elderly is different from CML in younger patients. IFN treatment of elderly patients with chronic phase CML achieved the same survival advantage as in younger patients at lower dosage. It was not more toxic than in younger patients and should therefore be considered first-line treatment also in the elderly.
